VJOncology is committed to improving our service to you

ESMO Breast 2020 | Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355

VJOncology is committed to improving our service to you

Sara Tolaney

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, outlines the role of immunotherapy in triple-negative breast cancer (TNBC), discussing IMpassion130 (NCT02425891) and KEYNOTE-355 (NCT02819518) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter